A PHASE III, RANDOMIZED, OPEN-LABEL, SPONSOR-BLINDED, MULTICENTER STUDY OF DURVALUMAB IN COMBINATION WITH TREMELIMUMAB ± LENVATINIB GIVEN CONCURRENTLY WITH TRANSARTERIAL CHEMOEMBOLIZATION (TACE) COMPARED TO TACE ALONE IN PATIENTS WITH LOCOREGIONAL HEPATOCELLULAR CARCINOMA (EMERALD-3)
- Registry ID
- D910VC00001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ASTRAZENECA CANADA INC
- Start date
- 2022-11-04
- Last update
- 2022-03-03
Conditions
Related clinical trials
- RADIATION THERAPY FOLLOWED BY DURVALUMAB (MEDI4736) AND TREMELIMUMAB AND
SURGERY VERSUS RADIATION THERAPY FOLLOWED BY SURGERY FOR RESECTABLE
HEPATOCELLULAR CARCINOMA. A RANDOMIZED WINDOW OF OPPORTUNITY TRIAL
(DARTS)
- A MULTICENTER, OPEN LABEL, NON-RANDOMIZED FIRST-IN-HUMAN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY,PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF BAY 3547926 ALONE, AND IN COMBINATION, IN PARTICIPANTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
- PERIOPERATIVE THERAPY WITH DURVALUMAB PLUS TREMELIMUMAB FOR PATIENTS WITH RESECTABLE HEPATOCELLULAR CARCINOMA (HCC) - A PHASE II TRIAL (NEOTOMA)
- ATEZOLIZUMAB AND BEVACIZUMAB PRE-LIVER TRANSPLANTATION FOR PATIENTS WITH HEPATOCELLULAR CARCINOMA BEYOND MILAN CRITERIA: A FEASIBILITY STUDY
- A STUDY TO EVALUATE THE EFFICACY OF PROPRANOLOL IN BOOSTING IMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA, CHOLANGIOCARCINOMA AND PANCREATIC ADENOCARCINOMA (BLOCKED)
- A RANDOMIZED, MULTI-CENTER, DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE 3 STUDY OF NIVOLUMAB AND IPILIMUMAB, NIVOLUMAB MONOTHERAPY, OR PLACEBO IN COMBINATION WITH TRANS-ARTERIAL CHEMOEMBOLIZATION (TACE) IN PATIENTS WITH INTERMEDIATE-STAGE HEPATOCELLULAR CARCINOMA (HCC)
View on source registry